Advanced Lung Cancer clinical trials

Explore recruiting advanced lung cancer clinical trials.

Recruiting advanced lung cancer studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Advanced Lung Cancer trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase I/II, Open-label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD2936 Anti TIGIT/Anti-PD-1 Bispecific Antibody in Participants with Advanced or Metastatic Non small Cell Lung Cancer (ARTEMIDE-01).

Belgium, Netherlands, Denmark, France, Spain

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

A Randomized, Double-Blind, Phase 3 Trial of Adagrasib plus Pembrolizumab plus Chemotherapy vs. Placebo plus Pembrolizumab plus Chemotherapy in Participants with previously Untreated, Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer with KRAS G12C Mutation (KRYSTAL-4)

Hungary, Romania, Netherlands, Austria, Croatia, France +9 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

HERTHENA-Lung01: A Phase 2 Randomized Open-Label Study of Patritumab Deruxtecan (U3-1402) in Subjects with Previously Treated Metastatic or Locally Advanced EGFR mutated Non-Small Cell Lung Cancer (NSCLC)

Germany, Netherlands, France, Italy, Belgium, Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase Ib/II, multi-site, open-label, two-part trial to evaluate the efficacy, safety, pharmacokinetics, and recommended combination dose of BNT324 with BNT327 in participants with advanced lung cancer

Spain, France, Italy, Poland

Phase I and Phase II (Integrated)- Other EU CTIS Study details

IFCT-2502 LIMPID Phase II trial assessing 1st line and 2nd line treatment in patients with advanced Non-Small Cell Lung Cancer and Interstitial Lung Disease

France

Therapeutic exploratory (Phase II) EU CTIS Study details

A study to test Aumolertinib in European participants with genetically linked advanced Lung Cancer

Bulgaria

Human Pharmacology (Phase I)- Other EU CTIS Study details

Advanced Lung Cancer trials by city

Advanced Lung Cancer in Toronto Advanced Lung Cancer in Vancouver Advanced Lung Cancer in Montreal Advanced Lung Cancer in Calgary Advanced Lung Cancer in Edmonton Advanced Lung Cancer in Ottawa Advanced Lung Cancer in Winnipeg Advanced Lung Cancer in Quebec City Advanced Lung Cancer in Hamilton Advanced Lung Cancer in Kitchener Advanced Lung Cancer in London Advanced Lung Cancer in Halifax Advanced Lung Cancer in New York Advanced Lung Cancer in Los Angeles Advanced Lung Cancer in Chicago Advanced Lung Cancer in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease